AFLIBERCEPT C4318H6788N1164O1304S32 (115 kDa-with glycosylation)

Slides:



Advertisements
Similar presentations
ECCO ESMO 2011 GI Cancer Updates “ VELOUR” Study Author: J Tabernero et al Reviewed by: Dr. Scott Berry Date posted: October.
Advertisements

ERYTHROPOIESIS- STIMULATING AGENTS. Patients who are no longer able to produce enough erythropoietin in the kidneys may benefit from treatment with.
P.A. Tang 1, S. J. Cohen 1, G. Bjarnason 1, C. Kollmannsberger 1, K. Virik 1, M. J. MacKenzie 1, J. Brown 1, L. Wang 1, A. Chen 2, M. J. Moore 1 1 Princess.
ANTI-VEGF Recent Advances in DR. VEGF- Vascular Endothelial Growth factor is an important growth factor for angiogenesis and is necessary for normal angiogenesis.
Adalimumab Drugbank ID : DB00051
Anti-thymocyte Globulin (Equine)
Omalizumab Drugbank ID : DB00043
Antihemophilic Factor
DB05829 PREOTACT C845H1343N223O243S kDa.
Brodalumab Drugbank ID : DB11776 Molecular Weight (Daltons) :144,000
Darbepoetin alfa Drugbank ID : DB
ECCO ESMO 2011 GI Cancer Updates “VELOUR” Study
ID DB06372 RILONACEPT CATEGORY Immunosuppressive Agents.
Reteplase Drugbank ID : DB00015
Serum albumin Albunex Optison™ IV infusion
Necitumumab Drugbank ID :DB09559 Molecular Weight (Daltons) :144800
Anti-thymocyte Globulin (Rabbit)
Dulaglutide Drugbank ID : DB09045.
Epoetin alfa Drugbank ID : DB00016
Elotuzumab Drugbank ID : DB06317.
DB08870 Brentuximab vedotin C6476H9930N1690O2030S –151.8 kDa.
TALIGLUCERASE ALFA DB08876 C2580H3918N680O727S g/mol
Subcutaneous injection
Anistreplase Drugbank ID : DB00029
ID DB08935 OBINUTUZUMAB C6512H10060N1712O2020S kDa CATEGORY
Pegvisomant(DB00082) Approved Drug
Ramucirumab Protein chemical formula : C6374H9864N1692O1996S46
Metreleptin Drugbank ID :DB09046
Peginterferon beta-1a Drugbank ID :DB00060
Asfotase Alfa Drugbank ID : DB09105.
Muromonab (DB00075) Approved and Investigational Drug
Insulin Degludec Drugbank ID :DB09564
Salmon Calcitonin Drugbank ID : DB00017
Nivolumab Drugbank ID : DB09035 Molecular Weight (Daltons) :
TERIPARATIDE DB06285 C181H291N55O51S kDa CATEGORY
RAXIBACUMAB DB08902 C6320H9794N1702O1998S kDa CATEGORY
DB08879 BELIMUMAB C 6358 H 9904 N 1728 O 2010 S kDa CATEGORY Monoclonal antibodies.
Romiplostim(DB05332) Approved Drug
Serum Albumin Iodinated(DB00064) Approved Drug
Pembrolizumab Drugbank ID :DB09037 Half life : 28 days.
Streptokinase (DB00086) Approved Drug
Asparaginase Erwinia chrysanthemi
Panitumumab (Approved investigational) DB01269
Natalizumab (Approved, Investigational)
Cetuximab Drugbank ID : DB00002
Daratumumab Drugbank ID : DB09043.
Vedolizumab Protein chemical formula : C6528H10072N1732O2042S42
Pegfilgrastim Drugbank ID : DB00019
Imiglucerase Protein chemical formula : C2532H3854N672O711S16
Ofatumumab Drugbank ID : DB06650 Molecular Weight (Daltons) :146100
Atezolizumab Drugbank ID : DB11595.
Galsulfase (Approved investigational) DB01279
Basiliximab (DB00074) Approved and Investigational Drug
Idarucizumab Molecular Weight (Daltons) : 47766
DB08914 OCRIPLASMIN C1214H1890N338O348S kDa CATEGORY
Ibritumomab(DB00078) Approved Drug
Sebelipase alfa Protein chemical formula : C1968H2945N507O551S15
Retina Centre of Ottawa Clinical Trials
Thyrotropin Alfa Drugbank ID : DB00024
Pegademase bovine Drugbank ID : DB00061
Anthrax immune globulin human
Ixekizumab Drugbank ID : DB11569 Molecular Weight (Daltons) :146,158
Tositumomab (DB00081) Approved Drug
DB01270 Category : Ophthalmics
Eptifibatide (DB00063) Approved and Investigational Drug
Methoxy polyethylene glycol-epoetin beta
ID DB06273 TOCILIZUMAB.
ID DB06720 VELAGLUCERASE ALFA CATEGORY Enzymes.
DB00090  Laronidase C3160H4848N898O881S kDa IV infusion.
Obiltoxaximab Drugbank ID :DB05336 Molecular Weight (Daltons) :148000
Presentation transcript:

AFLIBERCEPT C4318H6788N1164O1304S32 (115 kDa-with glycosylation) DB08885 AFLIBERCEPT C4318H6788N1164O1304S32 (115 kDa-with glycosylation) Eylea Regeneron Pharmaceuticals Zaltrap Regeneron Pharmaceuticals CATEGORY Antineoplastic Agents Ophthalmics

DESCRIPTION Aflibercept is a recombinant fusion protein that comprises of two main components: the vascular endothelial growth factor (VEGF) binding portions from the extracellular domains of human VEGF receptors 1 and 2 which is then fused to the Fc portion of human IgG1. Structurally, Aflibercept is a dimeric glycoprotein with a protein molecular weight of 96.9 kilo Daltons (kDa). It contains approximately 15% glycosylation to give a total molecular weight of 115 kDa. All five putative N-glycosylation sites on each polypeptide chain predicted by the primary sequence can be occupied with carbohydrate and exhibit some degree of chain heterogeneity, including heterogeneity in terminal sialic acid residues, except at the single unsialylated site associated with the Fc domain. Aflibercept, as an ophthalmic agent, is used in the treatment of macular edema following Central Retinal Vein Occlusion (CRVO) and neovascular Age-Related Macular Degeneration (AMD). Ziv-aflibercept, under the brand name Zaltrap, was developed as an injection for treatment of metastatic colorectal cancer. FDA approved in November 18, 2011 and EMA approved in November 2012.

INDICATION The opthalmic agent is used for the treatment of neovascular (wet) age-related mascular degeneration (AMD) and macular edema following central retinal vein occulsion (CRVO). The systemic injection, known as ziv-aflibercept, in combination with 5-fluorouracil, leucovorin, irinotecan-(FOLFIRI), is for the treatment of metastatic colorectal cancer that is resistant to or progressed following treatment with oxaliplatin. PHARMACODYNAMICS Compared to other anti-VEGF drugs like bevacizumab and ranibizumab, aflibercept has a higher binding affinity to VEGF-A (Kd = 0.5 pM). MECHANISM OF ACTION Ablibercept is a recombinant fusion protein that acts as a decoy receptor for the ligands, vascular endothelial growth factor-A (VEGF-A) and placental growth factor (PIGF). It prevents these ligands to binding to endothelial receptors, VEGFR-1 and VEGFR-2, to suppress neovascularization and decrease vascular permeability. This ultimately will slow vision loss or the progression of metastatic colorectal cancer.

ABSORPTION In patients with wet AMD and CRVO, the mean peak plasma concentration (Cmax) was 0.02 mcg/mL and 0.05 mcg/mL respectively. These concentrations were reached in 1 to 3 days. Aflibercept did not accumulate when administered as repeated doses intravitreally every 4 weeks. VOLUME OF DISTRIBUTION After intravenous injection of aflibercept, the volume of distribution is 6 L Metabolism Because aflibercept is a protein, it is expected to be broken down via proteolysis into smaller peptides and amino acids. The cytochrome P450 enzyme system is not involved in the metabolism of aflibercept.

Intravitreal HALF-LIFE = 7.13 days in humans Terminal elimination half-life of free aflibercept in plasma was 5 to 6 days after IV injection of 2 - 4 mg/kg dose. CLEARANCE When cancer patients were given 2-9 mg/kg every 2 or 3 week; 1 hour IV infusion of aflibercept the typical estimated clearances were as follows: CL of free aflibercept (CLf) = 0.88 L/day; CL of bound aflibercept (CLf) = 0.19 L/day; Patients clear free aflibercept faster if they had low albumin or high alkaline phosphatase levels. TOXICITY For all intravitreal VEGF inhibitors, there is increased risk of stroke and myocardial infarction. An increase in intraocular pressure may also occur. When used intravenously, most common adverse reactions were leukopenia, diarrhea, neutropenia, proteinuria, AST increased, stomatitis, fatigue, thrombocytopenia, ALT increased, hypertension, weight decreased, decreased appetite, epistaxis, abdominal pain, dysphonia, serum creatinine increased, and headache.

AFLIBERCEPT EYLEA (for macular degeneration)  Intravitreal inj AFLIBERCEPT EYLEA (for macular degeneration)  Intravitreal inj. Zaltrap ((ziv‑aflibercept: for colorectal cancer) IV infusion EYLEA (aflibercept) is a recombinant fusion protein consisting of portions of human VEGF receptors 1 and 2 extracellular domains fused to the Fc portion of human IgG1 formulated as an iso-osmotic solution for intravitreal administration. Aflibercept is a dimeric glycoprotein with a protein molecular weight of 97 kilodaltons (kDa) and contains glycosylation, constituting an additional 15% of the total molecular mass, resulting in a total molecular weight of 115 kDa. Aflibercept is produced in recombinant Chinese hamster ovary (CHO) cells. Zaltrap (ziv-aflibercept) is a recombinant fusion protein consisting of Vascular Endothelial Growth Factor fused to the Fc portion of human IgG. Zaltrap injection for intravenous infusion is indicated for patients with metastatic colorectal cancer (mCRC).

Derived from recombinant CHO cells DOSAGE (Eyela): 2 mg (0.05 mL or 50 microliters) administered by intravitreal injection every 4 weeks (monthly) for the first 12 weeks (3 months), followed by 2 mg (0.05 mL) via intravitreal injection once every 8 weeks (2 months). Although EYLEA may be dosed as frequently as 2 mg every 4 weeks (monthly), additional efficacy was not demonstrated when EYLEA was dosed every 4 weeks compared to every 8 weeks DOSAGE (Zaltrap): 4 mg per kg as an intravenous (IV) infusion over 1 hour every two weeks. Administer ZALTRAP prior to any component of the FOLFIRI regimen on the day of treatment VIAL DESCRIPTION: EYLEA is a sterile, clear, and colorless to pale yellow solution. EYLEA is supplied as a preservative-free, sterile, aqueous solution in a single-use, glass vial designed to deliver 0.05 mL (50 microliters) of EYLEA (40 mg/mL in 10 mM sodium phosphate, 40 mM sodium chloride, 0.03% polysorbate 20, and 5% sucrose, pH 6.2).

VIAL DESCRIPTION Zaltrap is available in single-use vials in two strengths: 100 mg/4 mL (25 mg/mL) and 200 mg/8 mL (25 mg/mL). Zaltrap is dosed as 4 mg/kg as an intravenous infusion over 1 hour, every 2 weeks. Serious side effects include hemorrhage, GI perforation and compromised wound healing. Based on animal data, Zaltrap may cause fetal harm. Zaltrap should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. It is not known whether Zaltrap is excreted in human milk. Because many drugs are excreted in human milk and because of the potential for serious side effects in nursing infants, a decision should be made as to whether to discontinue nursing or to discontinue the drugs, taking into account the important of the drug to the mother. The safety and effectiveness of Zaltrap has not been examined in the pediatric population.

ADVERSE REACTION: Eyela: Hives; difficult breathing; swelling of your face, lips, tongue, or throat. Zaltrap: Severe and sometimes fatal hemorrhage, including gastrointestinal (GI) hemorrhage, has been reported in the patients who have received ZALTRAP in combination with FOLFIRI. Monitor patients for signs and symptoms of GI bleeding and other severe bleeding. Do not administer ZALTRAP to patients with severe hemorrhage. GI perforation including fatal GI perforation can occur in patients receiving ZALTRAP. Discontinue ZALTRAP therapy in patients who experience GI perforation. DOSAGE 2 mg (0.05 mL or 50 microliters) administered by intravitreal injection every 4 weeks (monthly) for the first 12 weeks (3 months), followed by 2 mg (0.05 mL) via intravitreal injection once every 8 weeks (2 months). Although EYLEA may be dosed as frequently as 2 mg every 4 weeks (monthly), additional efficacy was not demonstrated when EYLEA was dosed every 4 weeks compared to every 8 weeks

PROTEIN SEQUENCE FOR AFLIBERCEPT SDTGRPFVEMYSEIPEIIHMTEGRELVIPCRVTSPNITVTLKKFPLDTLIPDGKRIIWDSRKGFIISNATYKEIGLLTCEATVNGHLYKTNYLTHRQTNTIIDVVLSPSHGIELSVGEKLVLNCTARTELNVGIDFNWEYPSSKHQHKKLVNRDLKTQSGSEMKKFLSTLTIDGVTRSDQGLYTCAASSGLMTKKNSTFVRVHEKDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPG

PATENTS Country Patent Number Approved Expires (estimated) United States 7306799 2005-03-25 2020-05-23 United States 7531173 2009-05-12 2026-02-02 United States 7374758 2008-05-20 2020-05-23 United States 7608261 2009-10-27 2027-06-14 United States 7070959 2006-07-04 2020-05-23 United States 7374757 2008-05-20 2020-05-23

REFERENCES Eyela http://www.ncbi.nlm.nih.gov/pubmed/25200895 http://www.ncbi.nlm.nih.gov/pubmed/24740170 http://www.ncbi.nlm.nih.gov/pubmed/22354219 http://www.ncbi.nlm.nih.gov/pubmed/23461161 Zaltrap http://www.ncbi.nlm.nih.gov/pubmed/25395483 http://www.ncbi.nlm.nih.gov/pubmed/25394166 http://www.ncbi.nlm.nih.gov/pubmed/25393440 http://www.ncbi.nlm.nih.gov/pubmed/25378900 http://www.ncbi.nlm.nih.gov/pubmed/25378873